- Home
- PRAX vs CFR Comparison
PRAX vs CFR Comparison
Compare PRAX & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRAX | CFR |
|---|---|---|
| Founded | 2015 | 1868 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 8.1B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRAX | CFR |
|---|---|---|
| Price | $332.84 | $144.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 13 |
| Target Price | ★ $519.60 | $141.46 |
| AVG Volume (30 Days) | 540.8K | ★ 577.9K |
| Earning Date | 02-19-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.73% |
| EPS Growth | N/A | ★ 11.84 |
| EPS | N/A | ★ 9.92 |
| Revenue | $7,463,000.00 | ★ $2,191,042,000.00 |
| Revenue This Year | N/A | $9.08 |
| Revenue Next Year | $29,535.93 | $4.52 |
| P/E Ratio | ★ N/A | $14.74 |
| Revenue Growth | ★ 364.98 | 9.62 |
| 52 Week Low | $26.70 | $100.31 |
| 52 Week High | $328.60 | $148.46 |
Technical Indicators
Market Signals| Indicator | PRAX | CFR |
|---|---|---|
| Relative Strength Index (RSI) | 65.37 | 62.69 |
| Support Level | $302.00 | $144.99 |
| Resistance Level | $328.60 | $148.29 |
| Average True Range (ATR) | 16.93 | 3.81 |
| MACD | -0.13 | 0.32 |
| Stochastic Oscillator | 95.16 | 68.54 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $53 billion in assets (as of September 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.